Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Denosumab Demonstrates Survival Benefit in Postmenopausal Women
December 9th 2015A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.
Dr. Goy on John Theurer Cancer Center Milestone
December 9th 2015Andre Goy, MD, MS, chairman and director, chief of Lymphoma, director, Clinical and Translational Cancer Research, discusses an upcoming event at John Theurer Cancer Center in honor of the institution's 25th anniversary of its first bone marrow transplant.
Adjuvant Capecitabine Improves Survival in HER2-Negative Breast Cancer
Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and surgery.
Blinatumomab Shows High CR Rates Across Two ALL Studies
Monotherapy with blinatumomab demonstrated high complete remission or CR with partial hematological recovery rates in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.
Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLL
December 8th 2015Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
No Safety Concerns in Trial of Ibrutinib to Early-Stage CLL
Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.
Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma
December 8th 2015Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the ClÃnica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple Myeloma
December 7th 2015Robert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.
Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell Malignancies
December 7th 2015Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
High Response Rates Seen With CAR T-Cell Therapies for NHL
Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.
Adding Rituximab to Chemo Boosts Survival in Subgroup of ALL Patients
Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.
Eltrombopag Improves Response Rates in Severe Aplastic Anemia
More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.
Dr. Kumar on Tourmaline-MM1 Study for Multiple Myeloma
December 6th 2015Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the phase III Tourmaline-MM1 study, which compared the efficacy of the addition of ixazomib to lenalidomide and dexamethasone with lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Oral Ixazomib Triplet Improves PFS in Myeloma
An all orally administered treatment regimen containing ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Dr. Steensma on Midostaurin for Patients With AML
December 6th 2015David P. Steensma, MD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a phase III study comparing midostaurin with placebo in combination with daunorubicin cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) with FLT3 mutations.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
